Inhibiting acetate metabolism shows promise in breast cancer model
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
List view / Grid view
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
Disruption of the MFF-VDAC1 complex could lead to a potential therapeutic target for cancer.
A small molecule inhibitor has been observed to activate a dramatic reduction in tumour growth in EBV-associated tumours...
An engineered DNA vaccine that induces a robust and specific immune response against the disease, also provides complete protection...
A DNA vaccine developed through the use of unique tumour antigens could lead the way towards vaccinating people against cancer...
Low-density lipoprotein cholesterol could be treated by using synthetic DNA-encoded monoclonal antibodies to inhibit PCSK9...
DNA vaccine optimised to cross-react with several MAGE-A isoforms generates a robust immune response and antitumour activity in a pre-clinical model of melanoma...
Scientists have found a mechanism through which mutant p53 enhances metastasis by controlling tumour metabolism...
New research explains how accumulation of chemically modified lipids interferes with the function of a protein involved in the antitumor function of dendritic cells...
A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans...
Depletion of B cells in the tumour micro-environment shows anti-tumour activity in patients with advanced metastatic melanoma...
Scientists have described a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA...
Scientists discover, a potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer...
14 July 2016 | By Victoria White, Digital Content Producer
The US National Institutes of Health has awarded $30 million in annual funding to help advance science towards a cure for HIV...
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...